WASHINGTON, June 23, 2025 – The U.S. Food and Drug Administration has approved lenacapavir as the world’s first twice-yearly injectable for HIV prevention—a landmark moment in the fight against one of the globe’s most enduring public health challenges. The drug, developed as a form of pre-exposure prophylaxis (PrEP), requires just two injections a year and […]